1-benzyl-4-(3-bromo-phenylamino)-3-(3-chloro-phenylamino)-pyrazolo[3,4-d]pyrimidine | 183739-52-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 1-benzyl-4-(3-bromo-phenylamino)-3-(3-chloro-phenylamino)-pyrazolo[3,4-d]pyrimidine
• 英文别名: 1-benzyl-4-N-(3-bromophenyl)-3-N-(3-chlorophenyl)pyrazolo[3,4-d]pyrimidine-3,4-diamine
• CAS: 183739-52-8
• 化学式: C₂₄H₁₈BrClN₆
• 分子量: 505.804
• InChiKey: FHVSLJYHPXLXOE-UHFFFAOYSA-N

物化性质

• 沸点：
  689.9±55.0 °C(predicted)
• 密度：
  1.52±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  67.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-benzyl-4-(3-bromo-phenylamino)-3-(3-chloro-phenylamino)-pyrazolo[3,4-d]pyrimidine 在 三氯化铝 作用下， 以 苯 为溶剂， 以39%的产率得到4-(3-bromo-phenylamino)-3-(3-chloro-phenylamino)-1H-pyrazolo[3,4-d]pyrimidine
  参考文献：
  名称：

  Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors:  4-(Phenylamino)pyrazolo[3,4-d]pyrimidines

  摘要：

  In the course of the random screening of a pool of CIBA chemicals, the two pyrazolopyrimidines 1 and 2 have been identified as fairly potent inhibitors of the EGF-R tyrosine kinase. Using a pharmacophore model for ATP-competitive inhibitors interacting with the active site of the EGF-R protein tyrosine kinase (PTK), the class of the pyrazolo[3,4-d]pyrimidines was then optimized in an interactive process leading to a series of 4-(phenylamino)-1H-pyrazolo[3,4-d]-pyrimidines as highly potent inhibitors of the EGF-R tyrosine kinase. The most potent compounds 13, 14, 15, 17, 19, 22, 26, 28, and 30 of this series inhibited the EGF-R PTK with IC50 values below 10 nM. High selectivity toward a panel of nonreceptor tyrosine kinases (c-Src, upsilon-Abl) and serine/threonine kinases (PKC alpha, CDK1) was observed. In cells, EGF-stimulated cellular tyrosine phosphorylation was inhibited by compounds 13, 15, 19, 22, and 23 at IC50 values below 50 nM, whereas PDGF-induced tyrosine phosphorylation was not affected by concentrations up to 10 mu M, thus indicating high selectivity for the inhibition of the ligand-activated EGF-R signal transduction pathway. Compounds 15 and 19 inhibited proliferation of the EGF-dependent MK cell line with IC50 values below 0.5 mu M. In addition, two compounds, 9 and 11, showing satisfactory oral bioavailability in mice after oral administration, exhibited good in vivo efficacy at doses of 12.5 and 50 mg/kg in a nude mouse tumor model using xenografts of the EGF-R overexpressing A431 cell line. From SAR studies, a binding mode for 4-(phenylamino)-1H-pyrazolo[3,4-d]pyrimidines, especially for compound 15, at the ATP-binding site of the EGF-R tyrosine kinase is proposed. 4-(Phenylamino)-1H-pyrazolo[3,4-d]pyrimidines represent a new class of highly potent tyrosine kinase inhibitors which preferentially inhibit the EGF-mediated signal transduction pathway and have the potential for further evaluation as anticancer agents.

  DOI：

  10.1021/jm970124v
• 作为产物：
  描述：

  1-benzyl-3-(3-chloro-phenylamino)-4-hydroxy-pyrazolo[3,4-d]pyrimidine 在 三氯氧磷 作用下， 以 乙醇 为溶剂， 反应 9.5h， 生成 1-benzyl-4-(3-bromo-phenylamino)-3-(3-chloro-phenylamino)-pyrazolo[3,4-d]pyrimidine
  参考文献：
  名称：

  Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors:  4-(Phenylamino)pyrazolo[3,4-d]pyrimidines

  摘要：

  In the course of the random screening of a pool of CIBA chemicals, the two pyrazolopyrimidines 1 and 2 have been identified as fairly potent inhibitors of the EGF-R tyrosine kinase. Using a pharmacophore model for ATP-competitive inhibitors interacting with the active site of the EGF-R protein tyrosine kinase (PTK), the class of the pyrazolo[3,4-d]pyrimidines was then optimized in an interactive process leading to a series of 4-(phenylamino)-1H-pyrazolo[3,4-d]-pyrimidines as highly potent inhibitors of the EGF-R tyrosine kinase. The most potent compounds 13, 14, 15, 17, 19, 22, 26, 28, and 30 of this series inhibited the EGF-R PTK with IC50 values below 10 nM. High selectivity toward a panel of nonreceptor tyrosine kinases (c-Src, upsilon-Abl) and serine/threonine kinases (PKC alpha, CDK1) was observed. In cells, EGF-stimulated cellular tyrosine phosphorylation was inhibited by compounds 13, 15, 19, 22, and 23 at IC50 values below 50 nM, whereas PDGF-induced tyrosine phosphorylation was not affected by concentrations up to 10 mu M, thus indicating high selectivity for the inhibition of the ligand-activated EGF-R signal transduction pathway. Compounds 15 and 19 inhibited proliferation of the EGF-dependent MK cell line with IC50 values below 0.5 mu M. In addition, two compounds, 9 and 11, showing satisfactory oral bioavailability in mice after oral administration, exhibited good in vivo efficacy at doses of 12.5 and 50 mg/kg in a nude mouse tumor model using xenografts of the EGF-R overexpressing A431 cell line. From SAR studies, a binding mode for 4-(phenylamino)-1H-pyrazolo[3,4-d]pyrimidines, especially for compound 15, at the ATP-binding site of the EGF-R tyrosine kinase is proposed. 4-(Phenylamino)-1H-pyrazolo[3,4-d]pyrimidines represent a new class of highly potent tyrosine kinase inhibitors which preferentially inhibit the EGF-mediated signal transduction pathway and have the potential for further evaluation as anticancer agents.

  DOI：

  10.1021/jm970124v

文献信息

• [EN] PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF<br/>[FR] DERIVES DE PYRAZOLE ET LEURS PROCEDES DE PREPARATION
  申请人：NOVARTIS AG

  公开号：WO1996031510A1

  公开（公告）日：1996-10-10

  (EN) 4-Amino-1H-pyrazolo[3,4-d]pyrimidine derivatives of formula (I) wherein the symbols are as defined in claim (1), and intermediates for their manufacture are described. The compounds of formula (I) inhibit especially the tyrosine kinase activity of the receptor for epidermal growth factor and can be used, for example, in the case of epidermal hyperproliferation (psoriasis) and as anti-tumour agents.(FR) La présente invention décrit des dérivés de 4-amino-1H-pyrazolo[3,4-d]pyrimidine de formule (I), dans laquelle les symboles sont tels que définis dans la revendication (1), ainsi que les intermédiaires pour leur fabrication. Les composés de formule (I) inhibent tout particulièrement l'activité de tyrosine-kinase du récepteur du facteur de croissance épidermique et peuvent être utilisés, par exemple, dans le cas d'une hyperprolifération épidermique (psoriasis) et comme agents anti-tumoraux.

  本发明涉及4-氨基-1H-吡唑并吡啶衍生物，其通用化学式为(I)，其中各符号按权利要求1所定义。描述了相应的中间体，用于合成这些分子。分子的结构式为： 4-氨基-1H-吡唑并吡啶衍生物的通用化学式为： 这些化合物的表现特性可以在权利要求1中找到详尽解释。这些化合物可以通过特定的方法合成。它们的进步特性尤其是其对表皮生长因子受体的靶向抑制能力，这使得它们对治疗某些皮肤疾病（如光面性 enabled conditions，即银Haschick氏病（Psoriasis））以及某些癌症具有潜在的用途。
• [EN] FUSED PYRAZOLE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION<br/>[FR] DERIVES DE PYRAZOLE CONDENSES ET PROCEDES POUR LEUR PREPARATION
  申请人：NOVARTIS AG

  公开号：WO1998014449A1

  公开（公告）日：1998-04-09

  (EN) 4-Amino-1H-pyrazolo[3,4-d]pyrimidine derivatives of formula (I) in which m, n and v are each, independently of one another, 0 or 1, R is hydrogen or methyl, R1 is chlorine or methyl which is in each case located in position 3 of the phenyl radical, X is the group NH(CH-R7)t in which t is 0, 1 or 2 and R7 is hydrogen, or the group (C[R3]-R4)q, in which q is 0, and R2 is nitro, cyano, amino, dimethylamino-lower-alkyleneamino, 4-pyridylcarbonylamino, 2-methylpropanoylamino, tert-butyloxycarbonylamino, or methyl which is substituted by amino, C1-C5-alkanoylamino, tert-butyloxycarbonylamino or benzoylamino, with the exception of 3-(3-aminobenzylamino)-4-(3-chlorophenylamino)-1H-pyrazolo[3,4-d]pyrimidine are described. The compounds of formula (I) inhibit in particular the tyrosine kinase activity of the receptor for epidermal growth factor and can be used, for example, for epidermal hyperproliferation (psoriasis) and as antitumor agents.(FR) L'invention concerne des dérivés de 4-amino-1H-pyrazolo(3,4-d)pyrimidine présentant la formule (I). Dans cette dernière, m, n et v sont chacun indépendamment l'une de l'autre égal à O ou 1. R représente hydrogène ou méthyle, R1 représente du chlore ou méthyle qui est dans chaque cas placé en position 3 du radical phényle, X est le groupe NH(CH-R7)t dans lequel t est égal à 0, 1 ou 2, et R7 représente hydrogène, ou le groupe (C(R3)-R4)q dans lequel q est égal à 0, et R2 est égal à nitro, cyano, amino, diméthylamino-alkylèneamino inférieur, 4-pyridylcarbonylamino, 2-méthylpropanoylamino, tert-butyloxycarbonylamino, ou méthyle qui est substitué par amino-alcanoylamino C1-C5, tert-butyloxycarbonylamino ou benzoylamino, à l'exception de 3-(3-aminobenzylamino)-4-(3-chlorophénylamino)-1H-pyrazolo (3,4-d)pyrimidine . Les composés selon la formule (I) inhibent en particulier l'activité de la tyrosine kinase du récepteur du facteur de croissance épidermique, et peuvent être utilisés, par exemple, pour l'hyperprolifération épidermique (psoriasis) et comme agents anti-tumoraux.

  本发明涉及一种4-氨基-1H-吡咯[3,4-d]吡咯衍生物，其化学式为(I)，化学式(I)中的m、n和v各自独立地取0或1。R为氢或甲基，R1为氯或甲基，其在每个情况下位于苯基基团的位置3。X为氨基-CH(R7)t基团，其中t为0、1或2，R7为氢；或为基团(C(R3])-R4)q，其中q为0，R2为硝基、羰基、氨基、二甲基氨基-下端乙基氨基、4-吡啶酰胺、2-甲基丙酰胺基、 tert-butyl-O-acet酰胺基、或甲基，后者被氨基-C1-C5-烯基酰胺基、 tert-butyl-O-acet酰胺基或苯酰酰胺基取代。除3-(3-氨基-苯基氨基)-4-(3-氯ophenty)氨基-1H-吡咯[3,4-d]吡咯外，所述化合物抑制酪氨酸激酶活性，特别地，它们可以用于角化素增多症(如光屑症)的治疗以及抗肿瘤用途。
• PYRAZOLE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF
  申请人：Novartis AG

  公开号：EP0819129A1

  公开（公告）日：1998-01-21
• US5981533A
  申请人：——

  公开号：US5981533A

  公开（公告）日：1999-11-09
• Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors:  4-(Phenylamino)pyrazolo[3,4-<i>d</i>]pyrimidines
  作者：Peter Traxler、Guido Bold、Joerg Frei、Marc Lang、Nicholas Lydon、Helmut Mett、Elisabeth Buchdunger、Thomas Meyer、Marcel Mueller、Pascal Furet

  DOI：10.1021/jm970124v

  日期：1997.10.1

  In the course of the random screening of a pool of CIBA chemicals, the two pyrazolopyrimidines 1 and 2 have been identified as fairly potent inhibitors of the EGF-R tyrosine kinase. Using a pharmacophore model for ATP-competitive inhibitors interacting with the active site of the EGF-R protein tyrosine kinase (PTK), the class of the pyrazolo[3,4-d]pyrimidines was then optimized in an interactive process leading to a series of 4-(phenylamino)-1H-pyrazolo[3,4-d]-pyrimidines as highly potent inhibitors of the EGF-R tyrosine kinase. The most potent compounds 13, 14, 15, 17, 19, 22, 26, 28, and 30 of this series inhibited the EGF-R PTK with IC50 values below 10 nM. High selectivity toward a panel of nonreceptor tyrosine kinases (c-Src, upsilon-Abl) and serine/threonine kinases (PKC alpha, CDK1) was observed. In cells, EGF-stimulated cellular tyrosine phosphorylation was inhibited by compounds 13, 15, 19, 22, and 23 at IC50 values below 50 nM, whereas PDGF-induced tyrosine phosphorylation was not affected by concentrations up to 10 mu M, thus indicating high selectivity for the inhibition of the ligand-activated EGF-R signal transduction pathway. Compounds 15 and 19 inhibited proliferation of the EGF-dependent MK cell line with IC50 values below 0.5 mu M. In addition, two compounds, 9 and 11, showing satisfactory oral bioavailability in mice after oral administration, exhibited good in vivo efficacy at doses of 12.5 and 50 mg/kg in a nude mouse tumor model using xenografts of the EGF-R overexpressing A431 cell line. From SAR studies, a binding mode for 4-(phenylamino)-1H-pyrazolo[3,4-d]pyrimidines, especially for compound 15, at the ATP-binding site of the EGF-R tyrosine kinase is proposed. 4-(Phenylamino)-1H-pyrazolo[3,4-d]pyrimidines represent a new class of highly potent tyrosine kinase inhibitors which preferentially inhibit the EGF-mediated signal transduction pathway and have the potential for further evaluation as anticancer agents.